Kevin M. Flanigan, MD, is the Director of the Center for Gene Therapy at the Abigail Wexner Research Institute of Nationwide Children’s Hospital (NCH), where he holds the Robert F. & Edgar T. Wolfe Foundation Endowed Chair in Neuromuscular Research. Dr. Flanigan trained in Neurology and Neuromuscular Disease at the Johns Hopkins Hospital, followed by a post-doctoral fellowship in Human Molecular Biology and Genetics at the University of Utah. After 14 years on the faculty in Utah, he joined NCH in 2009. He is currently the director of the NCH P50-funded Wellstone Muscular Dystrophy Specialized Research Center and is a Professor of Pediatrics and Neurology at Ohio State University. His laboratory work is directed toward the identification of genetic modifiers of disease severity in the dystrophinopathies, and toward the molecular characterization and treatment of neuromuscular diseases, using both gene replacement and RNA-modifying therapies. His lab has a particular interest in AAV-delivered U7snRNAs modified to target specific exons in the DMD gene, which has led to a first-in-human clinical trial. He is an experienced clinical trialist and has conducted multiple clinical trials of gene transfer therapies in DMD, as well as the childhood neurodegenerative disorders mucopolysaccharidosis types 3A and 3B